404
IBS C Drug Market Report
IBS-C Drug Market Trends, Dynamics & Market Insights
IBS-C Drug Market, By Product (Linaclotide, Lubiprostone, Stimulant Laxatives, Others), By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region - COVID-19 Impact Analysis and Forecast to 2026.
The IBS-C drug market is expected to witness an impressive growth of 9.2% CAGR in the foreseeable future.
Catalent Pharmaceuticals Solutions (US), Nestle (Switzerland), Abbott Laboratories (US), Synergy Pharmaceuticals (US), Sucampo Pharmaceuticals (US), Novartis Pharma Ag (Switzerland), Astellas Pharmaceuticals (Japan), Ardelyx, Inc (US), Synthetic Biologics, Inc (US), and Teva Pharmaceutical Industries (Israel) are the key players in the IBS-C drug market.
Severe gastrointestinal infection, rising lifestyle-oriented diseases, a growing number of patients suffering from depression, and medical advancements are the factors driving the growth of IBS-C drug market.
North America accounted for the largest share in the IBS-C drug market in 2020.
The linaclotide segment accounted for a substantial share in the IBS-C drug market in 2020.
IBS-C Drug distributors, IBS-C Drug suppliers, IBS-C Drug manufacturers, Hospitals, Government bodies are the target audience in the IBS-drug market.